Compensatory HSV Mutants Against Host Antiviral Response
Author Information
Author(s): Shah Amish C., Parker Jacqueline N., Shimamura Masako, Cassady Kevin A.
Primary Institution: University of Pennsylvania, Department of Pediatrics, Children’s Hospital of Philadelphia
Hypothesis
Can engineered HSV mutants evade the host antiviral response to improve viral replication and efficacy as anti-tumor agents?
Conclusion
Newly developed HSV mutants show improved replication and anti-tumor properties by evading the host's antiviral response.
Supporting Evidence
- HSV mutants lacking the γ134.5 gene have been studied for their safety and efficacy in humans.
- Serial passage has been used to identify mutations that improve viral replication.
- Compensatory mutations can restore protein synthesis in HSV mutants.
Takeaway
Scientists are making changes to a virus to help it fight cancer better by avoiding the body's defenses.
Methodology
The review discusses the development of HSV mutants through serial passage selection and viral genome engineering.
Limitations
The study primarily focuses on laboratory findings, which may not fully translate to clinical outcomes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website